CBLL
Ceribell, Inc.
$19.56
-0.08 (-0.41%)
At close · Jul 10
Market Cap
$742.16M
Shares
37,942,700
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$19.56
Open$19.64
Day$19.43–19.80
52W$10.85–24.33
Avg vol 30d339K
Short int2.0M · 5.2% float · 4.4d
Short vol53%
Last earningsMay 11, 2026
DataOct 2024–Jul 2026
Filing10-Q · May 11
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+9%
above
Price vs 50-day avg
+4%
above
RSI (14)
55
neutral
MACD trend
Positive
52-week position
65%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+6%
trailing
6-month return
−14%
trailing
YTD return
−11%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
4 of 121 funds reported for Jun 30 · net +34.2K sh shares · +1 new
Insider flow
Distributing
Net -$6.1M over 90 days · 100% sells
Short interest
Falling
5.21% of float · ▼ -1.8% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
121 holders — near 1-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
88%
expanding
EPS growth
+57%
Y/Y
Free cash flow
$-41.6M
Balance sheet
$40.5M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
3.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 11, 2026
Revenue
· full year 2026
Initiated
$112M – $116M
prior FY $89.06M
midpoint +28.0% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+9%
Bullish
Price vs 50-day avg
+4%
Bullish
RSI (14)
55
Neutral
MACD trend
Positive
Bullish
52-week position
65%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $19 › 200d $18 — 50d above 200d
Institutional flow
Accumulating
4 of 121 funds reported for Jun 30 · net +34.2K sh shares · +1 new
Insider flow
Distributing
Net -$6.1M over 90 days · 100% sells
Short interest
Falling
5.21% of float · ▼ -1.8% MoM · 4.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
121 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $11
Now $20 · 65%
52-wk high $24
vs 200-day avg +9%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total active accounts | 680 | first quarter of 2026 | — |
| account base (hospitals) | 680 | Q1 2026 call | — |
| active accounts (hospitals) | 680 | Q1 2026 call | — |
| gross margin | 87% | Q1 2026 call | — |
|
|
|||
| net new account additions | 33 | Q1 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBLL
this stock
Ceribell, Inc.
|
$742.16M | -10.8% | +36.1% | — | 5.2% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBLL | +0.1% | +6.4% | -14.4% | +0.6% | -10.8% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -1.3% | +2.4% | -23.4% | -0.5% | -21.5% |